Minerva Neurosciences reported $-7989000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -113.02M 68.36M
Adma Biologics ADMA:US $ -21.48M 8.29M
ALKERMES ALKS:US -26585000 28.97M
AstraZeneca AZN:LN 878M 1.17B
Biocryst Pharmaceuticals BCRX:US $ -49.96M 53.62M
Bristol Myers Squibb BMY:US $ 2553M 90M
Dynavax Technologies DVAX:US $ 30.76M 49.95M
Eli Lilly And LLY:US $ 2404.3M 487.1M
Esperion Therapeutics ESPR:US $ -42989000 12.64M
GlaxoSmithKline GSK:LN 2.8B 1.91B
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Johnson & Johnson JNJ:US $ 5862M 1026M
Marinus Pharmaceuticals MRNS:US $ -16.71M 10.4M
Merk MRK:US $ 5569M 1994M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Neurocrine Biosciences NBIX:US $ 3.1M 39.4M
Novartis NOVN:VX 2.85B 290M
Novavax NVAX:US $ 209.29M 1034.26M
Pfizer PFE:US $ 9873M 5297M
Takeda 4502:JP Y -1619M 118103M
Vanda Pharmaceuticals VNDA:US $ -7.67M 16.3M